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ABSTRACT
THE IMPACT OF MUSCULAR STRENGTH ON
CARDIOVASCULAR DISEASE RISK FACTORS
Joel Ernest Harden
Old Dominion University, 2021
Director: Dr. Gena Gerstner

The purpose of this study was to determine the associations between isokinetic leg
muscular strength and cardiovascular disease (CVD) risk factor characterizations in Americans
aged 50 and older. Using a publicly available dataset from the National Health and Nutrition
Examination Survey (NHANES), a secondary analysis was conducted on participants (males ≥50
yrs; females ≥55 yrs; N=10,858) pooled from 1999 to 2002. CVD risk factors were determined
using the American College of Sports Medicine (ACSM) cutoff values, with all nine ACSM risk
factors analyzed. CVD risk factor characterization was determined by creating CVD risk factor
profiles (i.e., the total number of CVD risk factors an individual possesses), then separating
participants into low (0-2 CVD risk factors), moderate (3-5 CVD risk factors), and high (6-8
CVD risk factors) risk factor characterizations. Muscular strength was determined by isokinetic
maximal peak force (PF) of the leg extensors, both raw and normalized to body mass.
Normalized, but not raw, muscular strength was shown to be significantly inversely associated
with CVD risk factor characterization for both males and females (P<0.001). Additionally, when
adjusting for all other CVD risk factors, age (males: OR: 1.13, 95% CI: 1.11-1.15; females: OR:
1.12; 95% CI: 1.10-1.15) obesity (males: OR: 0.54; 95% CI: 0.40-0.72; females: OR: 0.58; 95%
CI: 0.41-0.82), and smoking status (males: OR: 1.72; 95% CI: 1.31-2.26; females: OR: 1.39;
95% CI: 1.04-1.86) were significantly associated with isokinetic leg extensor muscular strength
in both males and females, while blood glucose (OR: 1.41; 95% CI: 1.07-1.86) was only

associated with muscular strength in males. Evidence from the present study supports the notion
that muscular strength may have a protective effect against CVD. However, this association
must be shown independent of cardiorespiratory fitness (CRF) and in clinical trials before any
causative link can be established.
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NOMENCLATURE
ACSM

The American College of Sports Medicine

BMI

Body Mass Index

BP

Blood Pressure

CI

Confidence Interval

CRF

Cardiorespiratory Fitness

CVD

Cardiovascular Disease

DXA

Dual X-Ray Absorptiometry

HDL

High-Density Lipoprotein

LDL

Low-Density Lipoprotein

NHANES

National Health and Nutrition Examination Survey

nPF

Normalized Peak Force (N/Kg)

OR

Odds Ratio

PF

Peak Force (N)

PIR

Poverty Income Ratio
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CHAPTER I
INTRODUCTION
Problem Description
CVD is the number one cause of death in Americans, accounting for more than 600,000
deaths annually (1). Among those deaths, more than 90% are from individuals over the age of 55
(2). The risk of CVD can usually be identified for certain individuals or groups based on several
risk factors. The ACSM identifies eight risk factors (1-8) that increase and one risk factor (9)
that decreases the likelihood of cardiovascular events. They are: (1) age, (2) family history, (3)
smoking habits, (4) sedentary lifestyle, (5) body mass index (BMI), (6) high blood pressure (BP),
(7) high cholesterol, (8) high blood glucose, and (9) elevated high-density lipoprotein (HDL)
levels (3). As men over the age of 45 and women over the age of 55 are already at risk for CVD
(3), it is important for this population to have as few risk factors as possible to reduce incidents
of CVD. The NHANES data set provides an ideal sample of this population within the United
States.
Muscular strength has been demonstrated by several studies to have an inverse
relationship with all-cause mortality (4-7). Additionally, it has been suggested that muscular
strength may protect against key CVD risk factors specifically, including hypertension (4).
Several studies have examined clustered CVD risk factors, now known as CVD risk profiles, and
their relationship to cardiorespiratory fitness (CRF) (8-10); however, few have examined these
CVD risk profiles regarding muscular strength. Although some studies have found inverse
relationships between muscular strength and metabolic syndrome (11), obesity (12), and risk of
hypertension (13), research has been generally inconclusive or contradictory regarding muscular
strength and CVD risk factors. For instance, a study by Vaara et al. in 2014 (14) found no
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correlation of CVD risk factors with muscular strength. However, Vaara et al. had several
limitations in their study that are addressed in the present study, including a lower mean age of
participants (25 yrs.) and no female participants included. Examining muscular strength
compared to CVD risk factors in an older population than was used by Vaara et al. is especially
important because muscular strength has been shown to decrease with age (i.e., dynapenia) (15),
putting this population at higher risk of low muscular strength (15). Low muscular strength
within this population due to their age, in addition to their higher susceptibility to CVD risk
factors, provides a strong rationale for further examination and study.
An inverse correlation between leg isokinetic muscular strength and CVD risk factors in
older American populations would give further basis for research to find evidence of a potential
protective role of muscular strength in CVD risk management on a population-wide scale.
Results of this paper may indicate the potential protective nature of muscular strength against
CVD risk factors, without inferring causation. Thus, the overall objective of this project is to
determine the relationship between leg isokinetic muscular strength and CVD risk factors in
males over 50 and females over 55 years in the United States. Our study is unique in that we
used all nine ACSM risk factors to build/create NHANES participant CVD risk factor profiles,
which is the first study to have done so in relation to measures of raw and normalized muscular
strength.
Statement of Purpose
To determine the associations between isokinetic leg muscular strength and
cardiovascular disease risk factor characterization in Americans aged 50 and older within the
NHANES 1999-2002 data set.
Significance of Study
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The proposed project sought to fill a void in the CVD risk factor research regarding
NHANES, providing novel insight into the potential role of isokinetic leg muscular strength as
protective against CVD risk factors in older American populations.
Research Hypothesis
Older American individuals within the NHANES data set with higher muscular strength
will exhibit a lower CVD risk factor characterization.
Variables
Independent Variables
The independent variables in this study were considered the CVD risk factors as defined
by the ACSM: (1) age, (2) family history of CVD, (3) smoking status, (4) sedentary lifestyle, (5)
obesity, (6) hypertension, (7) blood glucose/diabetes, (8) total cholesterol, (9) high-density
lipoprotein (HDL) cholesterol.
Dependent Variables
The dependent variables in this study include isokinetic maximal strength as measured by
PF and normalized PF (to body mass).
Limitations
The NHANES data set only has the leg isokinetic muscular strength test during a 4-year
period (1999-2002), limiting the number of possible participants. Additionally, the NHANES
data set does not include measures of CRF in this 4-year period for adults 50 and older, making it
impossible to determine the impact of muscular strength independent of CRF. Several CVD risk
factor variables were defined in the present study using survey data (i.e., family history,
sedentary lifestyle) or a mix of survey data and physiological data (i.e., hypertension, blood
glucose/diabetes, and total cholesterol).
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Delimitations
Only subjects aged 50 years and older were included in the data set. Individuals with
incidence of myocardial infarction within the past 6 weeks, chest or abdominal surgery in the
past three weeks, severe back pain, knee or knee replacement surgery, or a history of brain
aneurysm or stroke were excluded from the muscular strength test by the NHANES protocol.
Operational Definitions
•

Muscular strength: maximal isokinetic leg muscular strength as measured by peak force
in Newtons of the leg extensors.

•

CVD risk factor profile: the total number of CVD risk factors that an individual has (i.e.,
an individual with 6 CVD risk factors has a CVD risk factor profile of 6).

•

CVD risk factor characterization: a delineation of low (0-2), moderate (3-5), or high (6-8)
based on the individuals CVD risk factor profile (i.e., an individual with 6 CVD risk
factors would have a CVD risk factor profile of 6 and be in the “high” characterization).

•

Sedentary lifestyle: a score of one out of four on the NHANES physical activity
questionnaire ([you sit/he/she sits] during the day and [do/does] not walk about very
much).

•

Hypertension: above the blood pressure threshold for hypertension (≥130 systolic or ≥80
diastolic) OR prescribed hypertensive medication (i.e., answered yes in the NHANES
blood pressure and cholesterol questionnaire to the question “Taking prescription for
hypertension”.

•

Diabetes/blood glucose: above the fasted blood glucose threshold for diabetes (125
mg/dL) OR told they have diabetes by a doctor (i.e., answered yes in the NHANES
diabetes questionnaire to the question “Doctor told you have diabetes”.
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•

Total cholesterol: low HDL cholesterol (≤ 40 mg/dL) OR high low-density lipoprotein
(LDL) cholesterol (≥130 mg/dL) OR taking cholesterol medication (i.e., answered yes in
the NHANES blood pressure and cholesterol questionnaire to the question “Now taking
prescribed medication)”.
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CHAPTER II
LITERATURE REVIEW

Throughout the literature regarding the development of CVD, nine main risk factors have
been identified and were reviewed within this paper. These risk factors include age, family
history, smoking status, sedentary lifestyle, obesity, hypertension, blood glucose/diabetes status,
cholesterol levels, and elevated HDL levels. All of these risk factors are also identified by the
ACSM CVD risk factor screening, and the values for each risk factor are listed in Table 1 (3).
Additionally, muscular strength has been suggested to have a protective effect against certain
CVD risk factors (4), demonstrating an inverse relationship with metabolic syndrome (11),
obesity (12), and risk of hypertension (13). The literature surrounding to what extent these
inverse relationships exist, what type of muscular strength may exhibit this protective effect, and
what CVD risk factors are affected by this protective effect were examined in this literature
review.
CVD Risk Factors
CVD risk factors refer to any behaviors, conditions, or habits that can increase an
individual’s chances of developing CVD. As previously mentioned, ACSM lays out a list of
CVD risk factors, including family history, sedentary lifestyle status, and smoking habits (3).
Other studies, however, commonly use risk factor profiles (16, 17), such as one by Yusuf et al.
(1998) comprised of (BP), blood cholesterol, body mass index (BMI), diabetes, and smoking
habits. Yusuf et al. (1998) specifically examined whether a CVD risk profile, and the measures
within one, can predict CVD. The researchers (17) designed the profile on a zero to five scale –
participants exhibiting no risk factors were given a profile score of zero, while those exhibiting
all five were given a profile score of five. The authors (17) examined these variables as they
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related to coronary heart disease, stroke, and all-cause mortality within 12,932 participants from
the first NHANES data set from 1971-1975 and their subsequent follow up in 1992. The
individuals were between 25 and 75 years old when they were first recorded in the NHANES
data set (17). Each individual risk factor was found to be significantly associated with
developing coronary heart disease (17). Additionally, high BP, high cholesterol, diabetes, and
current smoking were all significantly associated with risk of stroke, and high BP, diabetes, and
smoking were all significantly associated with all-cause mortality (17). Individuals with higher
risk profiles (multiple risk factors) were significantly more likely to develop coronary heart
disease, have a stroke, or die, and each risk significantly increased as more risk factors were
added. The results of the Yusuf et al. (1988) study demonstrated the ability of risk factor profiles
to predict development of CVD and even death, and cemented these 5 specific factors (BP,
cholesterol, diabetes, overweight, and smoking) as relevant risk factors when building a profile.
Table 1: CVD Risk Factors
CVD Risk
Factors
Age
Family History

Smoking

Sedentary
Lifestyle
Obesity

Hypertension/
High BP

Criteria
Men >45 years, women >55
years *
Heart attack, heart surgery,
sudden death for immediate
relative*
Current smoker or have quit
<6 months ago, exposure to
environmental smoke*
<3 days/week of exercise for
<3 months*
Body Fat Percent: 25% for
men and 35% for women†
BMI: BMI ≥30 or 25 kg/m2 is
defined as obese or
overweight†
Waist Circumference: >40
inches in men and >35 inches
in women*
Systolic 140 and higher,
diastolic 90 and higher*

Used as a Risk Factor in These
Studies
Dhingra and Vasan, 2012

Score
(+1)

Carnethon et al., 2003, Lloyd-Jones et
al., 2004

(+1)

Carnethon et al., 2003, Paisible et al.,
2015, Saydah et al., 2014, Yusuf et al.,
1998
Mainous et al., 2019

(+1)

Body Fat Percent: Anderssen et al.,
2007, Christou et al., 2005
BMI: Carnethon et al., 2003, Li et al.,
2017, Yang et al., 2003, Yusuf et al.,
1998

(+1)

Anderssen et al., 2007, Carnethon et
al., 2003, Paisible et al., 2015, Saydah

(+1)

(+1)
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Blood Glucose

>100 mg/dl*

High
Cholesterol

LDL >130 or HDL <40 or
taking medication for
cholesterol*

Elevated HDL

>60*

et al., 2014, Vaara et al., 2014, Yang et
al., 2003, Yusuf et al., 1998
Carnethon et al., 2003, Christou et al.,
2005, Li et al., 2017 ; Vaara et al.,
2014, Yang et al., 2003
Anderson et al., 1987, Anderssen et al.,
2007, Carnethon et al., 2003, Christou
et al., 2005, Paisible et al., 2015, Yusuf
et al., 1998
Anderssen et al., 2007, Carnethon et
al., 2003, Christou et al., 2005, Cooney
et al., 2009; Li et al., 2017, Saydah et
al., 2014, Vaara et al., 2014, Yang et
al., 2003

(+1)

(+1)

(-1)

*(3); †(18)
The first column, “CVD Risk Factors”, contains the CVD risk factors identified by the ACSM (3), while the second
column, “Criteria”, contains the measurements qualifying the risk factor. Column 3, “Used as a Risk Factor in
These Studies”, indicates which risk factors were included in the risk factor profiles of each study cited in this paper.
The final column, “Score”, references which risk factors increase the likelihood for CVD and which decrease its
likelihood. Elevated HDL is the only factor that decreases the likelihood of CVD and is thus denoted with “-1”
rather than “+1”.

Age
Age is significantly associated with the development of CVD, even listed as its own
baseline risk factor for CVD by the ACSM (3). Heart failure, usually caused by aspects of CVD
such as hypertension and coronary heart disease, is so uncommon in younger individuals that its
prevalence within 20-39-year-old people is only 0.1-0.2% (2). This number increases
dramatically as age does, with a 5-10% prevalence in 60-79-year-old people, and as high as 14%
in those 80 and older (2). Coronary heart disease, which itself makes up more than half of all
deaths from CVD, also increases with age, and nearly 82% of deaths attributable to coronary
heart disease come from individuals aged 65 or older (2).
Family History
A family history of CVD is well known as a risk factor for CVD, as noted by the ACSM
(3). When examining the participants in the Framingham heart study, which included over 5,000
residents of Framingham, Massachusetts and additionally more than 5,000 of the original
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participants’ offspring in follow-up examinations years down the line, a history of at least one
parent suffering premature CVD is associated with doubling the risk of CVD in men (19). It was
also reported that having at least one parent who had suffered premature CVD was associated
with a 70% higher incidence of CVD in women, although this result was non-significant (19).
Smoking
Smoking, especially cigarette smoking, is responsible for roughly one third of all CVD
deaths in the United States (20). CVD risk and smoking have a strong relationship, as the more
cigarettes one smokes, the longer they have been a smoker, and the younger the age of smoking
onset, the greater the chances of CVD developing (20). Environmental smoke, also sometimes
known as secondhand smoke, may increase risk of CVD in those who do not smoke at all by 2030% (20).
Sedentary Lifestyle
Sedentary lifestyle habits may be as harmful regarding CVD as obesity (21). Mainous et
al. (2019) examined individuals of a healthy BMI (BMI: 18.5-24.9) within the NHANES
regarding how much time they spent sitting per day and whether they met the ACSM
recommendations for weekly exercise (150 minutes or more of light-moderate exercise or 75
minutes of vigorous exercise per week). This was then compared to their risk for CVD based on
a CVD risk factor profile. The results showed that individuals who are not overweight but lead a
more sedentary lifestyle (do not meet ACSM recommended weekly exercise times and spend 7.7
or more hours per day sitting) are at as much risk for CVD as obese individuals (21).
Obesity
Obesity may be measured in several different ways. The most used measures within
CVD risk factor studies are body fat percent, BMI, and waist circumference. Body fat percent is
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often measured through skinfold calipers (8), bio-electrical impedance (18), and dual energy xray absorptiometry (DXA) (10), while BMI is a calculation based on height and weight (9, 10,
17, 18, 22), and waist circumference is simply a measure in inches or centimeters of the waist of
an individual (23). When examining obesity as measured by both BMI and body fat percent,
Christou et al. (2005) found that both higher body fat percent and BMI are associated with all
other metabolic risk factors and are associated with higher mortality rates from CVD. The
relationship the authors (10) found was a better predictor of CVD risk factors than aerobic
fitness, which is considered to have a protective effect against CVD. Additionally, BMI was
found to be associated with hemodynamic risk factors (10). From these results, BMI status
should be considered when examining CVD and constructing CVD risk profiles.
Hypertension
Clinically high BP is known as hypertension and has been defined as a systolic BP of at
least 140 and a diastolic BP of at least 90 (3). Increased BP is shown to increase prevalence of
CVD (24). One study, when examining participants in the NHANES data set, found that a BP of
140/90 is significantly more likely to predict CVD than a lower BP (24).
Cholesterol/HDL
Cholesterol is associated with CVD in two main ways. Firstly, high total cholesterol
levels are a CVD risk factor (3). When examining participants from the Framingham study, it
was found that in individuals under 50, a low total cholesterol level is associated with a lower
risk of mortality from CVD (25). Secondly, a type of cholesterol known as HDL has been
shown to have a protective effect against risk of CVD (26). HDL levels are strongly inversely
associated with CVD mortality at all ages, sexes, and risk levels, although slightly more
protective within women than within men (26).
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Blood Glucose and Diabetes
Blood glucose levels and diabetes are also an ACSM risk factor for CVD (3). According
to the CDC (27), fasted blood glucose levels of 100-125 mg/dL indicate that the individual is
pre-diabetic, while levels of 126 mg/dL and above indicate that the individual is diabetic. The
ACSM considers fasted blood glucose levels of 100 mg/dL or more, indicating both individuals
with pre-diabetes and individuals with diabetes, as a CVD risk factor (3). When comparing
dysglycemia in both individuals with pre-diabetes and those with diabeties, it was found that
both have a relationship to the development of CVD (28). However, this relationship may be
impacted by several other metabolic disorders observed within individuals with hyperglycemia
hyperglycemic (28).
Special Consideration: Metabolic Syndrome
Metabolic syndrome, a metabolic disorder caused by obesity (29) that consists of the
simultaneous metabolic disturbances of insulin resistance, obesity, atherogenic dyslipidemia, and
hypertension (30), shares many risk factors with CVD (29). The four defining aspects of
metabolic syndrome (insulin resistance, obesity, atherogenic dyslipidemia, and hypertension) are
all either direct CVD risk factors (obesity, dyslipidemia, and hypertension) or related to CVD
risk factors (insulin resistance is the cause of the risk factor blood glucose/diabetes (31)).
Therefore, in this paper, metabolic syndrome was discussed as a cluster of CVD risk factors in
relation to muscular strength, although it was not specifically analyzed separate from the
individual CVD risk factors that comprise it.
Muscular Strength
Muscular strength within this population (i.e., ≥ 50 years) may be lower than that of
younger populations, as muscular strength has been shown to decrease with age (15), even
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shown within the NHANES data set (32). Despite this, muscular strength has been suggested to
have a protective effect against certain CVD risk factors (4). It is important to examine to what
extent this protective effect may occur. Some studies have measured 1-repetition maximum
bench press, leg press, or back squat to define muscular strength and evaluate how they relate to
CVD risk factors (11, 12) ; however, the present study examines leg isokinetic strength as
represented by peak force of the quadriceps knee extensor at a single speed (60 degrees/second).
Isokinetic strength, which involves making a contraction while moving at a constant speed, may
be more useful to measure in this population than other types of strength (33). This is partially
because it is known to be related to functional performance (33), which is especially important as
people age. Additionally, increases in isokinetic strength have been shown to improve fall risk
in older individuals, which can greatly reduce their risk of injury as adults age (34). Other
measures, such as isometric handgrip strength, have been shown to be strongly associated with
isokinetic strength, but lower body isokinetic strength is known to be more functional in this
population (35).

Lee et al. (2015) (36) found that an intervention designed to increase

isokinetic muscular strength in women aged 65-75 years not only increased isokinetic muscular
strength but also lowered CVD risk factors such as BMI and percent body fat significantly as
compared to individuals who had gone through only an aerobic training intervention. This
suggests that isokinetic muscular strength may correlate to specific CVD risk factors. It is
known that muscular strength has an inverse relationship with all-cause mortality in the United
States (5-7), for which CVD is the largest contributor nationwide (1), especially in adults over 50
(2). However, several studies also show an inverse relationship between muscular strength and
specific risk factors (11-13). For instance, a study by Jackson et al. in 2010 found an inverse
relationship between muscular strength and the CVD risk factor of obesity. Using body fat
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percentage measures for obesity and a one-repetition max for both bench press and leg press for
muscular strength, the researchers (12) found as much as a 70% lower risk of excessive body fat
and excessive abdominal fat at the highest levels of muscular strength. Additionally, muscular
strength has been shown to be inversely associated with metabolic syndrome (11). A 44% lower
risk of metabolic syndrome in healthy-weight individuals and 39% in obese individuals was
shown at the highest levels of strength measured, even independent of age and body size (11).
Muscular strength is even inversely associated with hypertension (13). Over a 19-year
longitudinal study with 4,147 participants, researchers found a significant inverse relationship
between risk of hypertension and muscular strength; however, this relationship was only found in
prehypertensive participants (13).
From these studies, there appears to be a strong case for muscular strength having some
protective effect against certain CVD risk factors; however, not all studies have found the same
results. One study by Vaara et al. (2014) found no relationship between CVD risk factors and
muscular strength. This study (14) examined plasma glucose, HDL cholesterol levels,
triglyceride levels, and BP as CVD risk factors, and compared these to both muscular strength
and muscular endurance. Contrary to some of the previous studies (11-13), the researchers (14)
found that maximal muscle strength was not independently associated with the cluster of CVD
risk factors. However, they found that muscular endurance and CRF were both associated with
the risk factors independent of each other (14). Other studies have found inverse relationships
between CRF and CVD risk factors (8, 9, 37-44), suggesting that this relationship is a wellestablished phenomenon. Because of the contradiction in the literature regarding associations
between CVD risk factors and muscular strength, more research needs to be done to ascertain the
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true relationship. Additionally, differences in muscular strength between males and females (45)
indicate a need to analyze males and females separately.
National Health and Nutrition Examination Survey
Accordingly, the NHANES data set provides a uniquely useful sample for a measurement
of older Americans. NHANES includes age and demographic information in the survey, as well
as diabetes status, medical and health status, sedentary lifestyle status, BMI, waist
circumference, smoking and tobacco use, BP, blood glucose, and cholesterol information (27).
This information can be practically applied; for example, Yusuf et al. (1998) (17) used variables
from the NHANES data set to create and test CVD risk profiles. According to the NHANES
physicians’ examinations procedures manual, the procedures for these factors are:
(1) self-report for diabetes, smoking habits, and age; and
(2) a physician examination for BP and cholesterol; height and weight calculations for BMI;
waist measurements for waist circumference (27).
Several studies have previously used these variables or a subset thereof to successfully create
risk factor profiles (17, 22, 46). NHANES also examines muscular strength, in the form of knee
extensor strength. This is done through the use of a dynamometer to measure PF of the
quadriceps at the speed 60 deg/s (47). Several studies have successfully used the muscular
strength variable from the NHANES data set as well (48, 49). NHANES also provides a large
representative sample size nationwide of this population, according to Centers for Disease
Control and Prevention (2019), making it the ideal data set to study the relationship between
muscular strength and CVD risk factors in older Americans (50 and older).
Conclusion
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There are numerous CVD risk factors, many of which have been studied and clustered
together into CVD risk profiles (10, 16, 17). CVD is also the number one cause of death in
Americans, especially those over the age of 55 (1, 2). This population also experiences lower
muscular strength, as muscular strength has been shown to decrease with age (32, 50). Despite
this, muscular strength has been suggested to have a protective effect against CVD risk factors
(4), demonstrating an inverse relationship with risk factors such as obesity (12), metabolic
syndrome (11), and hypertension (13). While these inverse relationships suggest a potential
protective effect of muscular strength on CVD risk factors, not all research concurs, with at least
one study (14) finding no correlation between maximal muscular strength and CVD risk factors
and instead proposing muscular endurance as protective. Several studies have also found inverse
relationships between CVD risk factors and CRF instead (8, 9, 14). In light of the relatively
contradictory nature of the literature, more research ascertaining the true relationship between
muscular strength and CVD risk factors is warranted.
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CHAPTER III
METHODOLOGY
Sample
NHANES, the National Health and Nutrition Examination Survey, uses a stratified,
multi-stage, probability cluster design to generate a representative sample of the noninstitutionalized American population. The survey includes both an examination in a mobile
examination center (MEC) and a household interview. For the present study, data were drawn
from the 1999-2000 and 2001-2002 NHANES cycles. Participants within these two cycles were
screened for all variables involved, while some participants were excluded due to missing
variables on CVD risk factors. All surveyed males over the age of 50 that met inclusion criteria
were included in the examination, while only females aged 55 and older were included to
account for differences in age as a risk factor by gender as specified by the ACSM. After all
exclusion criteria, there were 10,858 participants available for full analysis, out of 25,316 total
individuals screened by the NHANES from 1999-2002.
Demographic, Anthropometric, and Health History Information
Relevant variables in these categories include age, gender, race/ethnicity, family poverty
income ratio (PIR) (a ratio of total family income over the federal poverty level), BMI, and CVD
history (any previous incidence of congestive heart failure, coronary heart disease, heart attack,
or stroke). Demographics and health history are taken as a self-report in the interview section of
NHANES, and race/ethnicity was categorized as non-Hispanic white, non-Hispanic black,
Mexican American, other Hispanic, and other non-Hispanic. PIR is a ratio of family income to
poverty threshold and is calculated by dividing family income by the poverty guidelines, specific
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to family size, depending on the year and state. BMI was calculated from height and weight
measured during the MEC component.
Muscular Strength
Only individuals 50 years old and older were eligible for the muscular strength test.
Individuals with incidence of myocardial infarction within the past 6 weeks, chest or abdominal
surgery in the past three weeks, severe back pain, knee or knee replacement surgery, or a history
of brain aneurysm or stroke were excluded from this test by the NHANES protocol. The testing
protocol consisted of a measurement of peak torque (Newton/meters) of the quadriceps’ knee
extensor strength at one speed, 60 degrees/second. Although peak torque was measured, peak
force (PF) (N) was recorded by NHANES. Measurements were taken using a Kin Com MP
dynamometer manufactured by Chattanooga Group, Inc., Chattanooga, TN. Six strength
measurements were recorded: three warm-up trials which accounted for familiarization, and
three test trials. The trial that recorded PF was used for further analyses. Measurements were
taken during the MEC portion of NHANES.
CVD Risk Factors
The presence of CVD risk factors in the participants was determined through self-report
in the interview, or through measurements in the examination or laboratory sessions, of
NHANES. Nine risk factors are included in this analysis: age, family history, smoking status,
sedentary lifestyle, overweight/obesity status, BP, cholesterol, blood glucose/diabetes, and HDL
levels. We determined risk factor profile by assigning each respondent a score from 0 to 8
depending on the number of risk factors present. Those who have HDL levels greater than or
equal to 60 mg/dL qualified for a negative risk factor, receiving a minus one on their risk factor
profile.
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Age
Age is self-reported during the household interview. For the purposes of this analysis, all
female participants below the age of 55 were not included in the sample, with all female
participants above the age of 55 included. For this reason, all participants did not need to be
coded for the age risk factor and age was used as the only continuous variable.
Family History
Family history includes whether a blood relative (father, mother, mother’s father,
mother’s mother, father’s father, father’s mother, brother, sister, or other) has had hypertension,
stroke, or a heart attack or angina in the past. This is measured through the interview section of
NHANES as a self-report and is originally measured as two separate variables (see Appendix 1),
which were coded as one dichotomous variable.
Smoking Status
Smoking status was determined by a serum cotinine cutoff value, which was measured
through a blood draw in the laboratory section of NHANES. Smoking status is coded as “yes” or
“no” in response to whether the individual had a value of greater than or equal to 3.0 ng/mL (51).
Serum cotinine was chosen over a smoking questionnaire included in NHANES because of
cotinine’s ability to predict exposure to multiple forms of tobacco, including environmental
smoke (52). The cutoff point of 3.0 ng/mL was chosen as to where participants would be
considered a “yes” regarding smoking status. This decision is based off of a previous analysis of
the NHANES population from 1999-2004 determining the 3.0 ng/mL cutoff point, rather than
the previously standard 14-15 ng/mL, was more accurate in determining actual smokers vs nonsmokers and did not overestimate the amount of non-smokers in a population (51).
Sedentary Lifestyle
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ACSM defines sedentary lifestyle as less than three days of 30 minutes of moderate
activity per week (3). Sedentary lifestyle status is taken in the interview section of NHANES;
however, it does not define activity congruently with ACSM. In the 1999-2000 and 2001-2002
NHANES cycles, this section is a self-report of the average level of physical activity each day
coded 1-4: (1) sit during the day and not walk about very much; (2) stand or walk about a lot
during the day but does not carry or lift things very often; (3) lifts light load or have to climb
stairs or hills often; (4) does heavy work or carries heavy loads. This variable was split into a
dichotomous variable (1 = sedentary; 2, 3, or 4 = not sedentary; Appendix 1).
Overweight/Obesity Status
Overweight/obesity status is determined during the examination portion of NHANES,
through a measurement of waist circumference (WC) in the MEC. WC cutoff values of >40 in
(101.6 cm) in males and >35 in (88.9 cm) in females were used to classify obesity. BMI (kg/m2)
values were taken through measurements of weight (kg) and standing height (m) but were
reported only as descriptive information, as waist circumference has been shown to be a better
predictor of visceral fat than BMI (53) and is used by the ACSM as a screening tool for the
obesity risk factor (3).
Hypertension
BP is measured during the examination section of NHANES in the MEC. A mercury
sphygmomanometer is used to take 3-4 BP measurements, and separate averages of systolic and
diastolic BPs were taken for the analysis. Hypertension is defined as a BP of (1) greater than
140 mmHg systolic or (2) greater than 90 mmHg diastolic, or (3) a self-report of a prescription of
antihypertensive medications. These three factors (Appendix 1) were used to created one
dichotomous variable, coded “yes” if the participant had at least one of the three, and “no” if the
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participant did not have any of the three. Participants missing up to two variables of either the
systolic measurement, diastolic measurement, or a self-report of hypertensive medication were
coded based off of the remaining variable(s).
Cholesterol
To determine total cholesterol levels, blood is taken during the laboratory section of
NHANES, where it is processed, stored, and shipped to the Johns Hopkins University
Lipoprotein Analytical Laboratory to be analyzed. A heparin-manganese (Mn) precipitation
method is used to determine HDL cholesterol levels. Low-density lipoprotein (LDL) cholesterol
is measured via a calculation of total cholesterol, HDL cholesterol, and triglycerides [LDLcholesterol] = [total cholesterol] – [HDL-cholesterol] – [triglycerides/5]. An (1) HDL of less
than 40 mg/dL, (2) LDL of greater than 130 mg/dL, or (3) self-report of taking cholesterol
medication is used to determine dyslipidemia and/or qualification as a CVD risk factor. Three
separate variables (Appendix 1) were used to created one dichotomous variable. Participants
missing up to two variables of either LDL measurement, HDL measurement, or a self-report of
cholesterol medication were coded based off of the remaining variable(s). Elevated HDL,
defined as HDL cholesterol >60 mg/dL (3), is included as a separate variable that lowers the
overall CVD risk profile (coded opposite: “no” meaning presence of elevated HDL >60 mg/dL).
Blood Glucose/Diabetes
Diabetes is measured as a self-report of a diagnosis from a healthcare professional during
the interview section of NHANES. Additionally, fasting plasma glucose is measured on
randomly selected participants who had fasted between 8 and 24 hours. Blood sugar is
considered diabetic if fasting blood glucose levels are above 125 mg/dL. This cutoff point was
used to be in congruence with the American Diabetes Association’s guidelines for diagnosing
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diabetes (54). This study did not distinguish between type 1 and type 2 diabetes. Two separate
variables (Appendix 1) were used to created one dichotomous variable, coded as “yes” if the
subject either (1) reported a diagnosis of diabetes in the past or (2) measured fasting blood
glucose levels above 125 mg/dL, and coded as “no” if the subject met neither of these conditions.
Participants missing either the diabetes self-report or the blood sugar measure were coded based
off of the remaining variable.
Statistical Analyses
Data files were downloaded from the NHANES website and processed using SAS (v 9.4;
SAS Institute Inc, Cary, North Carolina). The 1999-2000 and 2001-2002 files were merged, and
sampling weights (examination population-weights) were recalculated to account for four years
of combined data.
The mean ± standard deviation (SD) (i.e., age) and the prevalence (i.e., gender,
race/ethnicity, PIR categories, BMI categories, CVD history) of demographic factors were
calculated where appropriate. To assess the CVD risk factors associated with strength levels, a
multivariable model was conducted for males and females, separately. The ordinal logistic
regression model estimated the odds of PF status (i.e., quintiles; Q1 lowest, Q5 highest). The
ordering of categories within the outcome variable assessed the odds of having lower PF (i.e., Q1
vs. Q2-5; Q 1-2 vs. Q 3-5; Q1-3 vs. Q4-5; Q1-4 vs. Q 5). Predictor variables in the model
included: age (in years), family history (yes vs. no), smoking status (yes vs. no), sedentary
lifestyle (yes vs. no), obesity status (yes vs. no), high BP (yes vs. no), high cholesterol (yes vs.
no), low HDL cholesterol (yes vs. no), high blood sugar/diabetes (yes vs. no). Adjusted odds
ratios (OR) with 95% confidence intervals (CI) were calculated, with those not including 1.00
being deemed statistically significant. Mean (standard error) of PF and normalized PF (by body
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mass) were reported for each risk factor profile number (0-8). Two separate one-way analyses of
variance (ANOVA) using the weighted data were performed to evaluate differences in PF
between three risk factor groups (low: 0-2 risk factors, moderate: 3-5 risk factors, high: 6 risk
factors) for males and females, respectively. Scheffe post-hoc tests were used to obtain adjusted
P-values. A family-wise alpha level was set a priori at 0.05 for all analyses. Data were analyzed
using SAS software (v 9.4).
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CHAPTER IV
RESULTS
Demographics
Of the 13,341 participants meeting age requirements, 10,858 met all inclusion criteria
(6,080 male and 4,778 female). Characteristics and demographics are reported in Table 2. Of all
participants, 12.7% had reported previous incidence of CVD (14.8% of males and 9.9% of
females). The mean age of the participants was 66.4 years (64.9 males and 68.3 females), and
the majority of individuals sampled were either overweight (42.7% total, 48.1% male and 35.9%
female) or obese (29.9% total, 26.8% male and 33.8% female).

Table 2: Descriptive Characteristics of 10,858 Participants by Gender
Characteristic
Sample size
Age (years)
Race/ethnicity (%)

Category

All
10858
66.4 (9.4)

Male
6080
64.9 (9.8)

Female
4778
68.3 (8.5)

Mexican American
Other Hispanic
Non-Hispanic white
Non-Hispanic black
Other race/ethnicity

19.1%
3.9%
59.4%
15.2%
2.4%

18.5%
3.5%
61.3%
14.7%
2.1%

19.8%
4.5%
57.1%
15.8%
2.8%

< 1.5
1.5 to < 3.5
≥ 3.5

28.3%
34.7%
37.0%

25.3%
32.7%
42.0%

32.2%
37.2%
30.6%

< 18.5
< 25†
25 to < 30
≥ 30†
≥ 35

28.1 (5.2)
1.2%
27.4%
42.7%
29.9%
9.9%

27.9 (4.5)
1.0%
25.1%
48.1%
26.8%
7.0%

28.4 (5.9)
1.4%
30.3%
35.9%
33.8%
13.5%

Previous Incidence of CVD
No Previous Incidence of CVD

12.7%
87.3%

14.8%
85.2%

9.1%
90.9%

Poverty income ratio (%)

BMI mean (kg/m2)
BMI (%)

CVD History

†

Indicates that category is not mutually exclusive – i.e., values can range through both categories.
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Strength Quintiles and Odds Ratios
Table 3 presents the associations between quintiles (Q) of muscular strength and each
CVD risk factor, stratified by gender. The muscular strength quintiles, measured by PF, range
from (Q1 mean) 192.6 - (Q5 mean) 541.5 N for males and (Q1 mean) 191.9 – (Q5 mean) 490.4
N for females. Adjusted (accounting for all CVD risk factors) odds ratios (ORs) for each CVD
risk factor were calculated in Table 4. Controlling for all covariates, the odds of having lower
PF (i.e., Q1 v Q2-5; Q 1-2 v Q 3-5; Q1-3 v Q4-5; Q1-4 v Q 5) were increased in males who: had
elevated serum cotinine levels (OR = 1.72; 95% CI: 1.31-2.26), had diabetes (OR = 1.41; 95%
CI: 1.07-1.86), and were not obese as measured by waist circumference (OR = 0.54; 95% CI:
0.40-0.72). Furthermore, the odds of having a lower PF were increased in females who: had
elevated serum cotinine levels (OR = 1.39; 95% CI: 1.04-1.86) and were not obese by a measure
of waist circumference (OR = 0.58; 95% CI: 0.41-0.82). Additionally, the odds of having lower
PF increased with age in males (OR = 1.13; 95% CI: 1.11-1.15) and females (OR = 1.12; 95%
CI: 1.10-1.15). ORs were close to null and nonsignificant for all other CVD risk factors. When
we further controlled our models for CVD history, the results were similar. When examining the
CVD risk factors that make up metabolic syndrome (i.e., blood glucose/diabetes status, obesity,
dyslipidemia, and hypertension ), obesity in males and females and diabetes status in males were
significant in the regression model, similar to our original models.
CVD Risk Factor Profiles
Table 5 presents a CVD risk factor profile, showcasing the number of individuals
presenting with 0, 1, 2, 3, 4, 5, 6, 7, or 8 risk factors and their mean PF, stratified by gender.
Few of the individuals surveyed had either 0 risk factors (0.7% of males and 2.7% of females) or
8 risk factors (0.1% of males and 0.2% of females), with the plurality of individuals showcasing
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four risk factors (27.5% of males and 25.4% of females). For both males and females,
individuals presenting 0 risk factors had lower mean PF than individuals presenting 8 risk
factors. When normalizing PF to body mass (PF/body mass, N/Kg), the opposite is seen, with
individuals presenting 0 risk factors having greater normalized PF than individuals presenting 8
risk factors. Figure 1 depicts mean PF, body mass, and normalized PF in relation to CVD risk
factor profiles. As CVD risk factor profiles increased, mean PF increased among both males and
females. It was also shown that as CVD risk factor profiles increased, body mass also increased
for both males and females. However, when PF was normalized to body mass, the opposite was
seen, with normalized PF decreasing as CVD risk factor profiles increased across both males and
females. In Figure 2, the risk factor profiles were grouped and classified as low risk (0-2 risk
factors), moderate risk (3-5 risk factors), and high risk (6-8 risk factors), to account for few
participants with either 0 or 8 risk factors. Figure 2 showcases the distribution of normalized PF
across low-risk (0-2), moderate-risk (3-5), and high-risk (6-8) groups. There was a main effect
for group for both males and females (P<0.001). Scheffe post-hoc tests revealed that among both
males and females, the moderate-risk group had significantly lower normalized PF than the lowrisk group (P<0.001), and the high-risk group had significantly lower normalized PF than the
moderate (P=0.02), and low risk group (P<0.001). Females showed a difference of 0.4 N/Kg
(95% CI 0.35-0.49) between means of the low-risk group and the moderate-risk group, and a
difference of 0.4 N/Kg (95% CI: 0.29-0.50) between means of the moderate-risk group and the
high-risk group. Males showed a difference of 0.6 N/Kg (95% CI: 0.55-0.72) between means of
the low-risk group and the moderate-risk group, and a difference of 0.2 N/Kg (95% CI: 0.060.27) between means of the moderate-risk group and the high-risk group.
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Table 3: Weighted Prevalence of CVD Risk Factors Across Strength Quintiles in Males and Females
Male
Risk factors
Hypertension
No
Yes
Cotinine
No
Yes
Sedentary
No
Yes
Waist Circumference
No
Yes
Family History
No
Yes
Diabetes
No
Yes
Poor Cholesterol
No
Yes
Poor HDL
No
Yes

Female
Q2
Q3

All

Q1
Lowest

Q2

Q3

Q4

Q5
Highest

All

Q1
Lowest

Q4

Q5
Highest

32.3%
67.7%

26.8%
73.2%

22.1%
77.9%

35.4%
64.6%

31.0%
69.0%

39.9%
60.1%

23.4%
76.6%

21.3%
78.7%

21.8%
78.2%

24.1%
75.9%

26.6%
73.4%

22.8%
77.2%

72.0%
28.0%

70.4%
29.6%

73.4%
26.6%

72.9%
27.1%

71.5%
28.5%

71.7%
28.3%

84.7%
15.3%

85.3%
14.7%

79.1%
20.9%

89.1%
10.9%

83.9%
16.1%

85.7%
14.3%

75.9%
24.1%

72.9%
27.1%

76.0%
24.0%

82.7%
17.3%

77.8%
22.2%

71.1%
28.9%

76.9%
23.1%

73.6%
26.4%

72.8%
27.2%

81.7%
18.3%

79.6%
20.4%

76.5%
23.5%

49.4%
50.6%

52.8%
47.2%

64.0%
36.0%

53.5%
46.5%

41.7%
58.3%

42.0%
58.0%

33.1%
66.9%

38.0%
62.0%

39.6%
60.4%

41.5%
58.5%

24.4%
75.6%

24.0%
76.0%

78.4%
21.6%

82.3%
17.7%

79.8%
20.2%

85.1%
14.9%

75.4%
24.6%

73.5%
26.5%

70.0%
30.0%

72.5%
27.5%

71.8%
28.2%

75.0%
25.0%

64.6%
35.4%

66.8%
33.2%

64.3%
35.8%

60.3%
39.7%

54.4%
45.6%

64.8%
35.2%

66.8%
33.2%

69.7%
30.3%

70.0%
30.0%

69.9%
30.1%

72.7%
27.3%

69.7%
30.3%

68.8%
31.2%

69.2%
30.8%

38.2%
61.8%

38.2%
61.8%

40.1%
59.9%

43.6%
56.4%

35.3%
64.7%

35.5%
64.5%

53.3%
46.7%

59.7%
40.3%

55.8%
44.2%

49.7%
50.3%

51.4%
48.6%

50.7%
49.3%

12.3%
87.7%

17.0%
83.0%

14.5%
85.5%

9.9%
90.1%

11.1%
88.9%

11.4%
88.6%

43.4%
56.6%

46.5%
53.5%

46.4%
53.6%

51.4%
48.6%

37.5%
62.5%

36.5%
63.5%
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Table 4: Adjusted Odds Ratios (ORs) for Males and Females
Risk Factors

OR (95% CI)
Males

Females

Age

1.13 (1.11, 1.15)*

1.12 (1.10, 1.15)*

Hypertension

1.29 (0.95, 1.73)

0.80 (0.56, 1.15)

Cotinine
Sedentary
Lifestyle
Waist
Circumference
Family
History
Diabetes
Status
Cholesterol
Status

1.72 (1.31, 2.26)*

1.39 (1.04, 1.86)*

1.20 (0.87, 1.66)

1.27 (0.92, 1.75)

0.54 (0.40, 0.72)*

0.58 (0.41, 0.82)*

0.78 (0.49, 1.22)

1.35 (0.98, 1.87)

1.41 (1.07, 1.86)*

1.06 (0.78, 1.45)

0.80 (0.61, 1.07)

0.84 (0.66, 1.05)

HDL Status

0.93 (0.60, 1.44)

0.79 (0.58, 1.06)

Odds ratios (ORs) assessed the odds of having a lower level of PF (i.e., the odds of
being in Q1 v Q2-5; Q 1-2 v Q 3-5; Q1-3 v Q4-5; Q1-4 v Q 5) when controlling for
all other covariates.
* Statistical significance (i.e., 95% CI does not include 1.00).
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Table 5: Weighted Mean PF and Normalized PF Across CVD Risk Factor
Profiles in Males and Females
Males
CVD Risk Factor Profile

N

Percent

Mean PF (SE)

Normalized PF (SE)

0 Risk Factors

45

0.7

453.0 (15.0)

6.4 (0.2)

1 Risk Factor

337

5.5

446.2 (6.4)

5.9 (0.1)

2 Risk Factors

840

13.8

458.1 (4.2)

5.8 (0.0)

3 Risk Factors

1335

22.0

440.9 (3.0)

5.4 (0.0)

4 Risk Factors

1674

27.5

454.3 (3.0)

5.2 (0.0)

5 Risk Factors

1064

17.5

429.6 (3.7)

4.7 (0.0)

6 Risk Factors

615

10.1

481.0 (4.5)

5.1 (0.1)

7 Risk Factors

165

2.7

475.7 (11.4)

4.7 (0.1)

8 Risk Factors

5

0.1

502.0 (0.0)

4.6 (0.0)

Females
CVD Risk Factor Profile

N

Percent

Mean PF (SE)

Normalized PF (SE)

0 Risk Factors

128

2.7

272.0 (6.5)

4.5 (0.1)

1 Risk Factor

349

7.3

255.1 (3.5)

4.4 (0.1)

2 Risk Factors

695

14.5

274.3 (2.7)

4.3 (0.0)

3 Risk Factors

1116

23.4

271.5 (2.1)

3.9 (0.0)

4 Risk Factors

1215

25.4

285.1 (2.2)

3.8 (0.0)

5 Risk Factors

845

17.7

278.0 (3.1)

3.5 (0.0)

6 Risk Factors

315

6.6

285.3 (3.5)

3.6 (0.1)

7 Risk Factors

105

2.2

291.3 (7.2)

3.5 (0.1)

8 Risk Factors
10
0.2
315.5 (0.3)
4.4 (0.2)
Mean PF is the raw score mean of PF for all individuals with a specific risk factor profile.
Normalized PF is the mean of the PF/body mass (N/Kg) of each individual with a specific risk
factor profile. SE = standard error.
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Figure 1 CVD risk factor profiles (presenting 0-8 CVD risk factors) for males (A-C) and females (D-F).
For males, risk factor profiles are in relation to (A) mean PF (N), (B) mean body mass (Kg), and (C)
normalized PF (N/Kg). For females, risk factor profiles are in relation to (D) mean PF (N), (E) mean
body mass (Kg), and (F) normalized PF (N/Kg). Standard error is represented with error bars on each
graph.

Normalized PF (N/Kg)

Normalized PF (N/Kg)
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CVD Risk Factor Profile Groupings

Figure 2 CVD risk factor profiles grouped as low risk (0-2), moderate risk (3-5), and high risk (6-8) in
relation to normalized PF (N/Kg) in males (A) and females (B). The plots depict normalized PF (N/Kg)
values compared to CVD risk factor profile groupings with medians, upper and lower quartiles, and
minimum and maximum ranges. Outliers were identified as ○.
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CHAPTER V
DISCUSSION
The present study assessed the impact of CVD risk factors and profiles on isokinetic leg
extensor absolute and normalized maximal strength. Our findings provide further support that
the association between specific CVD risk factors (11-13, 55, 56) or CVD risk factor profiles (4,
57) and normalized muscular strength (normalized to either body mass or BMI) is inverse but
extend upon the current literature by demonstrating this inverse association using CVD risk
factor profiles that include all nine ACSM CVD risk factors, in a nationwide sample of American
males age 50 and older and females age 55 and older. These findings also indicate that there is a
positive association when only raw PF is considered, reinforcing ideas that normalized muscular
strength may be a better measure than raw muscular strength when measuring obese populations
(4, 56).
CVD and Exercise
Exercise has long been known to help with the prevention and management of CVD risk
(58-61). This is likely due to the fact that physical exercise (of any type) is associated with
improving mortality risk from aging (62, 63) and family history of CVD (64), smoking (65),
sedentary lifestyle (66, 67), obesity (68, 69), hypertension (70-73), high cholesterol (55, 71, 74,
75), diabetes (69, 76, 77), and HDL cholesterol (78), as well as decreased mortality from CVD
itself (61). The modality of exercise most associated with improvements in maximal muscular
strength is resistance training (58).
Resistance training is a form of exercise where the muscles are put under stress by
working against or holding a resistance (force or weight) that is applied (58). Although
resistance training was not analyzed in this study, it is known to increase maximal muscular
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strength in older individuals (58) and can effectively treat both sarcopenia (79, 80) and
dynapenia (80). Because of resistance training’s ability to increase maximal muscular strength
within this population (58), findings from this study suggest that resistance training interventions
may be able to assist in the treatment or management of CVD. Specific resistance training
recommendations for this population can be found in the ACSM’s position stand on “Exercise
and Physical Activity for Older Adults” (58). Resistance training has also been shown to
improve several ACSM CVD risk factors, such as waist circumference (81) and obesity (71),
total and LDL cholesterol (75, 82), hypertension (70, 72), and diabetes (83) and glycemic control
(77), although there is conflicting evidence regarding resistance training’s effects of blood
cholesterol (14, 76, 84). It is important to note that while resistance training can increase
maximal muscular strength, increasing normalized muscular strength may require dietary
interventions focused on reducing adiposity and lowering or maintaining total body mass (85).
CVD Risk Factor Profiles and Characterization on Isokinetic Peak Force
Previous research has shown that measures of muscular strength are inversely associated
with CVD risk factors such as hypertension (4), obesity (12), and metabolic syndrome (11), and
that normalized muscular strength may also demonstrate an inverse relationship with the
development of type 2 diabetes mellitus (56). However, our study is unique in that we used all
nine ACSM risk factors to build/create NHANES participant CVD risk factor profiles, which is
the first study to have done so in relation to measures of raw and normalized muscular strength.
Additionally, this study used isokinetic leg muscular strength, which measures force generated
by the leg extensors against a resistance at a constant speed (60 degrees per second) (86). This
was chosen because it is an effective measure of knee extension strength (86), which is
associated with gait speed (87) and functionality in older adults (33). Because muscular strength
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on its own is related to factors such as body mass, BMI, and waist circumference, it was decided
to analyze normalized PF as well as raw PF (4, 56). Figure 1 demonstrates the difference
between raw and normalized PF, and how body mass has masked the relationship between PF
and CVD risk factor profiles (i.e., mean PF for males and females slightly increase as CVD risk
factor profiles increase). When mean body mass for males and females is plotted against CVD
risk factor profiles, we can see that CVD risk factor profiles also increase steadily with mean
body mass similar to PF. Accounting for body mass, normalized PF for males and females
shows an inverse relationship with CVD risk factor profiles. It has been suggested that strength
may have a protective effect on CVD risk factors (4, 11, 88-91). In conjunction, our findings
may suggest that, within the U.S. population, higher leg extensor muscular strength (normalized
to body mass) may have a protective effect against CVD risk factors.
Every additional risk factor added to the CVD risk factor profile was associated with a
decreased normalized PF (Table 4), except in two cases. First, when increasing from 7 to 8 CVD
risk factors, there was an increase in normalized PF for both males and females. Second, when
going from 5 to 6 CVD risk factors, normalized PF increased for only males. The former is
likely due to the small number of participants with 8 risk factors (N=5 males; N=10 females);
however, the latter may be due to other factors. To correct for the small number of participants
with either very many or very few CVD risk factors, we grouped CVD risk factor profiles into
low (0-2 CVD risk factors), moderate (3-5 CVD risk factors), and high (6-8 CVD risk factors)
categories and plotted normalized muscular strength across them (Figure 2). For both males and
females, there were significant differences in normalized muscular strength based on CVD risk
factor characterization, with higher risk factor characterization having lower normalized PF. This
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provides further support for the significant inverse association seen between normalized
muscular strength and CVD risk factor profiles.
Adjusted Individual CVD Risk Factors (Accounting for Other Risk Factors)
The most prevalent risk factors in the present study sample were hypertension,
overweight/obesity (by waist circumference), high total blood cholesterol, and low HDL
cholesterol. The majority of participants had between two and five risk factors (N=8,784), with
only 1.6% (N=173) presenting zero risk factors (excluding age) and 0.1% (N=15) presenting
every risk factor. This is consistent with literature examining the prevalence of CVD risk factors
in this time frame (1999-2002), as hypertension has been found to affect between 40% and 80%
of U.S. individuals aged 50 years and older (92), while roughly 70% of individuals aged 60 years
and older in the U.S. were found to be either overweight or obese from 1999-2004 (93). In
addition, over 40% of adults age 20 and older in the U.S. have high blood cholesterol levels (94).
Hypertension, sedentary lifestyle, family history of CVD, high total cholesterol, and low
HDL cholesterol levels were not observed to be significantly associated with muscular strength
in either males or females, while diabetes status was not shown to be significantly associated
with muscular strength among females. Age, smoking status (by serum cotinine level), and waist
circumference were all shown to be significantly associated with muscular strength in both males
and females, when accounting for all other risk factors. However, diabetes status was shown to
be significantly associated with muscular strength in males, but not females.
Non-Significant CVD Risk Factors
Hypertension
Hypertension has been shown in previous research to be inversely associated with
muscular strength (13); however, Maslow et al. (13) found that this inverse association
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disappears after accounting for CRF. Contrary to this, Bakker et al. (55) found in 2017 that
resistance exercise, independent of CRF, is associated with a lower risk of developing metabolic
syndrome, which is characterized by glucose intolerance, insulin resistance, obesity,
dyslipidemia, and hypertension (55). Although previous authors have suggested that muscular
strength may be associated with hypertension regardless of CRF (4, 95), this was not observed
within this population.
Sedentary Lifestyle
It has been observed that although lower body muscular strength has some association
with sedentary lifestyles, other correlates such as gender, age, and BMI have much stronger
associations with physical activity levels (96); this may in part explain why sedentary lifestyle as
a CVD risk factor was not observed in this study to be independently associated with levels of
muscular strength.
Family History
A family history of CVD was also not observed to be significantly associated with
muscular strength in this study; this may in part be due to limitations with the specific years of
NHANES used. The ACSM defines a family history of CVD as a risk factor for CVD disease
only when that family member had a heart attack, bypass surgery, or sudden death before the age
of 55 (3). However, during the 1999-2002 NHANES data set, there was no way to determine at
what age a family member had had a heart attack, bypass surgery, or sudden death, and so the
defining criteria for this study were simply whether a blood relative had had a heart attack or
stroke, hypertension, or angina.
Total Cholesterol and HDL
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In regard to blood cholesterol, one study by Vaara et al. (14) found no associations
between muscular strength independent of CRF and LDL cholesterol. Similarly, this study
found no associations between either HDL or total cholesterol and muscular strength. However,
resistance training, which is known to increase maximal muscular strength within this population
(58), has been shown to increase blood HDL cholesterol in subjects with diabetes (76) and to
decrease LDL cholesterol when performed at high volumes (97). Other research has shown that
resistance training, even after increasing muscular strength, does not decrease LDL cholesterol
(76, 84).
Significant CVD Risk Factors
Age
Sarcopenia, the age-related loss of skeletal muscle mass and strength (98), and
dynapenia, the age-related loss of muscular strength without muscular disease or atrophy (15),
both lead to lower muscular strength among older individuals. Results from this paper show the
odds of having lower PF increases in both males (OR = 1.13; 95% CI: 1.11-1.15) and females
(OR = 1.13; 95% CI: 1.11-1.15) as they age, further confirming the veracity of these concepts.
The differences observed in normalized PF for the low, moderate, and high CVD risk factor
characterizations may indicate that this population of older individuals who are at a higher risk of
low muscular strength may especially benefit from resistance training interventions designed to
increase PF (99) as well as nutritional interventions designed to reduce adiposity (85).
Smoking
It has been observed that exposure to tobacco smoke is associated with decreased
muscular strength (100-103). It has been suggested by Petersen et al. (104) that this is due to an
impairment of muscle protein synthesis and the increased expression of genes regularly regarded
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as atrophy-related (such as MAFbx/atrogin-1) that accompanies exposure to tobacco smoke. It
has also been suggested that smoking may be related to increased muscular fatigue (105), as
cigarette smoke may cause both a reduced oxygen carrying capacity of the blood and impaired
oxygen delivery (106). Increased muscular fatigue can cause decreased maximal force output
(107). This would likely explain the inverse association observed within this paper regarding
muscular strength and serum cotinine, a measure of exposure to tobacco smoke.
Obesity
Obesity has also been shown to be positively associated with muscular strength (108,
109), as was seen in the present study. However, this is likely due to increased overall mass, so
many studies instead use normalized muscular strength to account for the high associations
between BMI and muscular strength (12, 110).
Blood Glucose and Diabetes
It has also been shown that normalized muscular strength has an inverse relationship with
type 2 diabetes mellitus (56) and that increasing muscular strength is associated with decreasing
risk for type 2 diabetes mellitus in men (111, 112). One potential explanation our results differ
based on gender may be due to sex hormone (i.e., testosterone and estrogen) differences between
men and women. For instance, low testosterone levels in men are associated with lower muscular
strength (113). Low testosterone levels in men are also associated with increased risk of diabetes
(114) and is common in men with type 2 diabetes (115-117). Therefore, testosterone levels in
men may effect both their levels of muscular strength and their diabetes status (118, 119).
Additionally, it has been proposed that estrogen is protective against CVD to some degree (120,
121), which is thought to be why women in general develop CVD 10 to 15 years later than men
(122). While it is not currently known whether estrogen has a protective effect against diabetes
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mellitus specifically, it has been shown that lower levels of circulating estradiol is related to
diagnosis of diabetes (123). Thus, differences in sex hormones may influence blood
glucose/diabetes status, which was significantly associated with muscular strength in males and
not in females. Unfortunately, sex hormone values for the 1999-2000 and 2001-2002 NHANES
data sets were not available.
ACSM Exercise Guidelines
The ACSM currently has recommendations for exercise training for older individuals
within their position stand, “Exercise and Physical Activity for Older Adults” (58). In this
position stand, the ACSM recommends that older adults engage in resistance training, as it can
substantially increase their maximal muscular strength (58). To safely and effectively
accomplish this, the ACSM along with the American Heart Association came up with guidelines
to recommend resistance training for older individuals (58). It is recommended that resistance
training be done at least twice weekly at moderate to vigorous intensities, with modalities
including progressive weight training programs, weight bearing calisthenics programs, stair
climbing, and other strengthening movements. It is recommended that 8-10 exercises per
session, for 8-12 repetitions per exercise, be done when resistance training for this population
(58).
Limitations and Future Research
There are several limitations in the present study. First, the NHANES 1999-2002 cycle
did not include any way to ascertain the age of family members when they were diagnosed with
CVD or had their first cardiac event. The ACSM defines a family history of CVD as a risk
factor for CVD disease only when that family member had a heart attack, bypass surgery, or
sudden death before the age of 55 (3). However, with the 1999-2002 NHANES data set, there
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was no way to determine at what age a family member had had a heart attack, bypass surgery, or
sudden death, and so the defining criteria for this study were simply whether a blood relative had
had a heart attack or stroke, hypertension, or angina. Additionally, ACSM defines sedentary
lifestyle as less than three days of 30 minutes of moderate activity per week (3). Sedentary
lifestyle status is taken in the interview section of NHANES; however, it does not define activity
congruently with ACSM. In the 1999-2000 and 2001-2002 NHANES cycles, this section is a
self-report of the average level of physical activity each day coded 1-4: (1) sit during the day and
not walk about very much; (2) stand or walk about a lot during the day but does not carry or lift
things very often; (3) lifts light load or have to climb stairs or hills often; (4) does heavy work or
carries heavy loads.
Self-report survey results were used in this study for five of the nine ACSM CVD risk
factors (family history, sedentary lifestyle, hypertension, diabetes, and cholesterol status); two of
these CVD risk factor variables were created solely with questionnaire data (sedentary lifestyle
and family history), while the other three combined questionnaire data with laboratory results to
create dichotomous variables (hypertension, diabetes status, and cholesterol status). This was
done to make sure individuals that exhibited the conditions (diabetes, hypertension, and
dyslipidemia) but were treating them with medication would still be included in the analyses.
It is not known whether the inverse association between normalized muscular strength
and CVD risk factor profiles is present when accounting for CRF. Unfortunately, the NHANES
did not include measures of CRF within the 1999-2002 data set for individuals 50 and older, and
thus we did not include CRF in our analyses. It is known that CRF has an inverse relationship
with CVD (8, 9), even when other risk factors such as smoking or high cholesterol are present
(37). It is possible that those with high normalized PF may also have high CRF, making CRF a
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confounding factor. Ruiz et al. (110), when examining the association between muscular
strength and risk of death from CVD, found inconclusive results when adjusting for CRF.
However, Bakker et al. (55) found that muscle strengthening resistance exercise, independent of
aerobic exercise, is associated with a lower risk of developing metabolic syndrome. Future
research will have to be done regarding the link between normalized muscular strength and CVD
risk factor profiles independent of CRF.
Additionally, this study was cross-sectional and observational, and therefore cannot
ascertain causation of any associations or trends seen. Clinical trials assessing the impact of
increased muscular strength on CVD risk factor profiles in this population would be necessary
before any sort of cause or protective effect could be deduced from the findings of this study.
Conclusions
While keeping in mind the limitations of cross-sectional, observational research, it was
seen here that normalized muscular strength, but not raw muscular strength, has an inverse
relationship with CVD risk factor profiles. This has been suggested to indicate a protective
effect of muscular strength against CVD (4), especially in an older population that has higher
prevalence of CVD as well as lower rates of muscular strength (15, 80, 96, 98, 124-132). Further
research reproducing these findings independent of CRF levels in participants will be necessary
before such an effect can be concluded. Additionally, men with diabetes were shown to have
significantly increased odds of low PF, but this was not observed for women. It is possible this
is due differences in sex hormone levels, but more research must be done to establish this link.
These findings may highlight a key role of normalized muscular strength in the prevention of
CVD. Additionally, the present study is unique both that (1) all nine ACSM CVD risk factors
were included for analysis, and (2) the sample included is a representative sample of the entire
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population of older individuals in the U.S. Interventions intent on increasing normalized
muscular strength in this population must address both increasing raw muscular strength with
exercise (resistance training) and decreasing body mass and/or excess adiposity with nutritional
strategies. Interventions such as these may be beneficial in lowering CVD risk factor profiles in
this population.

42

REFERENCES
1.
2.
3.
4.

5.
6.

7.

8.

9.

10.

11.

12.
13.

14.

15.
16.

17.

Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of
global methodologies of mortality measurement. Circulation. 2013;127(6):749-56.
Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly:
morbidity, mortality, and costs. Clinics in geriatric medicine. 2009;25(4):563-77.
Medicine ACoS. ACSM's guidelines for exercise testing and prescription. Lippincott
Williams & Wilkins; 2013.
Artero EG, Lee D-c, Lavie CJ et al. Effects of muscular strength on cardiovascular risk
factors and prognosis. Journal of cardiopulmonary rehabilitation and prevention.
2012;32(6):351.
Laukkanen P, Heikkinen E, Kauppinen M. Muscle strength and mobility as predictors of
survival in 75–84-year-old people. Age and ageing. 1995;24(6):468-73.
Metter EJ, Talbot LA, Schrager M, Conwit R. Skeletal muscle strength as a predictor of
all-cause mortality in healthy men. The Journals of Gerontology Series A: Biological
Sciences and Medical Sciences. 2002;57(10):B359-B65.
Rantanen T, Harris T, Leveille SG et al. Muscle strength and body mass index as longterm predictors of mortality in initially healthy men. The Journals of Gerontology Series
A: Biological Sciences and Medical Sciences. 2000;55(3):M168-M73.
Anderssen SA, Cooper AR, Riddoch C et al. Low cardiorespiratory fitness is a strong
predictor for clustering of cardiovascular disease risk factors in children independent of
country, age and sex. European Journal of Preventive Cardiology. 2007;14(4):526-31.
Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs Jr DR, Liu K.
Cardiorespiratory fitness in young adulthood and the development of cardiovascular
disease risk factors. Jama. 2003;290(23):3092-100.
Christou DD, Gentile CL, DeSouza CA, Seals DR, Gates PE. Fatness is a better predictor
of cardiovascular disease risk factor profile than aerobic fitness in healthy men.
Circulation. 2005;111(15):1904-14.
Jurca R, Lamonte MJ, Church TS et al. Associations of muscle strength and fitness with
metabolic syndrome in men. Medicine & Science in Sports & Exercise. 2004;36(8):13017.
Jackson AW, Lee DC, Sui X et al. Muscular strength is inversely related to prevalence
and incidence of obesity in adult men. Obesity. 2010;18(10):1988-95.
Maslow AL, Sui X, Colabianchi N, Hussey J, Blair SN. Muscular strength and incident
hypertension in normotensive and prehypertensive men. Medicine and science in sports
and exercise. 2010;42(2):288.
Vaara J, Fogelholm M, Vasankari T, Santtila M, Häkkinen K, Kyröläinen H.
Associations of maximal strength and muscular endurance with cardiovascular risk
factors. International journal of sports medicine. 2014;35(04):356-60.
Clark BC, Manini TM. What is dynapenia? Nutrition. 2012;28(5):495-503.
Anne-Lise P, Chang C-CH, So-Armah KA et al. Human immunodeficiency virus
infection, cardiovascular risk factor profile and risk for acute myocardial infarction.
Journal of acquired immune deficiency syndromes (1999). 2015;68(2):209.
Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of Multiple Risk Factor
Profiles on Determining Cardiovascular Disease Risk. Preventive Medicine.
1998;27(1):1-9.

43

18.

19.

20.
21.

22.

23.
24.

25.
26.

27.
28.

29.
30.
31.

32.

33.

34.

Li Y, Wang H, Wang K et al. Optimal body fat percentage cut-off values for identifying
cardiovascular risk factors in Mongolian and Han adults: a population-based crosssectional study in Inner Mongolia, China. BMJ open. 2017;7(4):e014675.
Lloyd-Jones DM, Nam B-H, D'Agostino Sr RB et al. Parental cardiovascular disease as a
risk factor for cardiovascular disease in middle-aged adults: a prospective study of
parents and offspring. Jama. 2004;291(18):2204-11.
Chen Z, Boreham J. Smoking and cardiovascular disease. In: Proceedings of the
Seminars in vascular medicine. 2002. p. 243-52.
Mainous III AG, Tanner RJ, Rahmanian KP, Jo A, Carek PJ. Effect of sedentary lifestyle
on cardiovascular disease risk among healthy adults with body mass indexes 18.5 to 29.9
kg/m2. The American journal of cardiology. 2019;123(5):764-8.
Yang EJ, Chung HK, Kim WY, Kerver JM, Song WO. Carbohydrate intake is associated
with diet quality and risk factors for cardiovascular disease in US adults: NHANES III.
Journal of the American College of Nutrition. 2003;22(1):71-9.
Lean M, Han T, Morrison C. Waist circumference as a measure for indicating need for
weight management. Bmj. 1995;311(6998):158-61.
Lamprea-Montealegre JA, Zelnick LR, Hall YN, Bansal N, de Boer IH. Prevalence of
hypertension and cardiovascular risk according to blood pressure thresholds used for
diagnosis. Hypertension. 2018;72(3):602-9.
Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up
from the Framingham Study. Jama. 1987;257(16):2176-80.
Cooney M, Dudina A, De Bacquer D et al. HDL cholesterol protects against
cardiovascular disease in both genders, at all ages and at all levels of risk.
Atherosclerosis. 2009;206(2):611-6.
NHANES - National Health and Nutrition Examination Survey Homepage. In: Centers
for Disease Control and Prevention; 2019.
Liu J, Grundy SM, Wang W et al. Ten-year risk of cardiovascular incidence related to
diabetes, prediabetes, and the metabolic syndrome. American heart journal.
2007;153(4):552-8.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The lancet.
2005;365(9468):1415-28.
Huang PL. A comprehensive definition for metabolic syndrome. Disease models &
mechanisms. 2009;2(5-6):231-7.
Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin
resistance and diabetes. Nature clinical practice Endocrinology & metabolism.
2007;3(1):46-56.
Looker AC, Wang C-Y. Prevalence of reduced muscle strength in older US adults:
United States, 2011-2012. US Department of Health and Human Services, Centers for
Disease Control and …; 2015.
Negrete R, Brophy J. The relationship between isokinetic open and closed chain lower
extremity strength and functional performance. Journal of Sport Rehabilitation.
2000;9(1):46-61.
Beebe JA, Hines RW, McDaniel LT, Shelden BL. An isokinetic training program for
reducing falls in a community-dwelling older adult: a case report. Journal of geriatric
physical therapy. 2013;36(3):146-53.

44

35.

36.

37.

38.

39.
40.

41.

42.

43.

44.

45.

46.

47.
48.

49.

Reed RL, Den Hartog R, Yochum K, Pearlmutter L, Ruttinger AC, Mooradian AD. A
comparison of hand‐held isometric strength measurement with isokinetic muscle
strength measurement in the elderly. Journal of the American Geriatrics Society.
1993;41(1):53-6.
Lee JS, Kim CG, Seo TB, Kim HG, Yoon SJ. Effects of 8-week combined training on
body composition, isokinetic strength, and cardiovascular disease risk factors in older
women. Aging clinical and experimental research. 2015;27(2):179-86.
Blair SN, Kampert JB, Kohl HW, III et al. Influences of Cardiorespiratory Fitness and
Other Precursors on Cardiovascular Disease and All-Cause Mortality in Men and
Women. JAMA. 1996;276(3):205-10.
SALLIS JF, PATTERSON TL, BUONO MJ, NADER PR. Relation of cardiovascular
fitness and physical activity to cardiovascular disease risk factors in children and adults.
American Journal of Epidemiology. 1988;127(5):933-41.
Slattery ML, Jacobs Jr DR. Physical fitness and cardiovascular disease mortality: the US
Railroad Study. American Journal of Epidemiology. 1988;127(3):571-80.
Williamson T, Moran C, Chirico D et al. Cancer and cardiovascular disease: The impact
of cardiac rehabilitation and cardiorespiratory fitness on survival. International Journal
of Cardiology. 2021;343:139-45.
Henriksson H, Henriksson P, Tynelius P et al. Cardiorespiratory fitness, muscular
strength, and obesity in adolescence and later chronic disability due to cardiovascular
disease: a cohort study of 1 million men. European heart journal. 2020;41(15):1503-10.
Gibbons LW, Blair SN, Cooper KH, Smith M. Association between coronary heart
disease risk factors and physical fitness in healthy adult women. Circulation.
1983;67(5):977-83.
Sobolski J, Kornitzer M, De Backer G et al. Protection against ischemic heart disease in
the Belgian Physical Fitness Study: physical fitness rather than physical activity?
American Journal of Epidemiology. 1987;125(4):601-10.
Katzmarzyk PT, Malina RM, Bouchard C. Physical activity, physical fitness, and
coronary heart disease risk factors in youth: the Quebec Family Study. Preventive
medicine. 1999;29(6):555-62.
Ryman Augustsson S, Bersås E, Magnusson Thomas E, Sahlberg M, Augustsson J,
Svantesson U. Gender differences and reliability of selected physical performance tests in
young women and men. Advances in Physiotherapy. 2009;11(2):64-70.
Saydah S, Bullard KM, Cheng Y et al. Trends in cardiovascular disease risk factors by
obesity level in adults in the United States, NHANES 1999‐2010. Obesity.
2014;22(8):1888-95.
NHANES 2001-2002: Muscle Strength Data Documentation, Codebook, and
Frequencies. In: Centers for Disease Control and Prevention; 2004.
Kuo H-K, Leveille SG, Yen C-J et al. Exploring how peak leg power and usual gait speed
are linked to late-life disability: data from the National Health and Nutrition Examination
Survey (NHANES), 1999–2002. American journal of physical medicine &
rehabilitation/Association of Academic Physiatrists. 2006;85(8):650.
Ostchega Y, Dillon CF, Lindle R, Carroll M, Hurley BF. Isokinetic leg muscle strength in
older Americans and its relationship to a standardized walk test: data from the national
health and nutrition examination survey 1999–2000. Journal of the American Geriatrics
Society. 2004;52(6):977-82.

45

50.
51.

52.

53.

54.

55.

56.

57.

58.
59.

60.
61.

62.
63.

64.

65.

Hurley BF. Age, gender, and muscular strength. Journals of Gerontology-Biological
Sciences and Medical Sciences. 1995;50:41-4.
Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal Serum Cotinine
Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different
Racial/Ethnic Groups in the United States Between 1999 and 2004. American Journal of
Epidemiology. 2008;169(2):236-48.
Seccareccia F, Zuccaro P, Pacifici R et al. Serum cotinine as a marker of environmental
tobacco smoke exposure in epidemiological studies: The experience of the MATISS
project. European Journal of Epidemiology. 2003;18(6):487-92.
Wang J-j, Wang H-j, Liu J-s, Ma J. [The association between body mass index, waist
circumference with body fat percent, and abdominal fat rate in overweight and obese
pupils]. Zhonghua Yu Fang Yi Xue Za Zhi. 2013;47(7):603-7.
Bakris G, Blonde L, Andrew M, Boulton J, D’Alessio D, de Groot M. American Diabetes
Association (ADA) Standards of Medical Care in Diabetes 2016 Cardiovascular disease
and risk management. Diabetes care. 2016;39(Suppl 1):S60-S71.
Bakker EA, Lee D-c, Sui X et al. Association of Resistance Exercise, Independent of and
Combined With Aerobic Exercise, With the Incidence of Metabolic Syndrome. Mayo
Clinic Proceedings. 2017;92(8):1214-22.
Jeon Y-J, Lee SK, Shin C. Normalized Hand Grip and Back Muscle Strength as Risk
Factors for Incident Type 2 Diabetes Mellitus: 16 Years of Follow-Up in a PopulationBased Cohort Study. Diabetes Metab Syndr Obes. 2021;14:741-50.
Silventoinen K, Magnusson PK, Tynelius P, Batty GD, Rasmussen F. Association of
body size and muscle strength with incidence of coronary heart disease and
cerebrovascular diseases: a population-based cohort study of one million Swedish men.
Int J Epidemiol. 2009;38(1):110-8.
Chodzko-Zajko WJ, Proctor DN, Singh MAF et al. Exercise and physical activity for
older adults. Medicine & science in sports & exercise. 2009;41(7):1510-30.
Fiuza-Luces C, Santos-Lozano A, Joyner M et al. Exercise benefits in cardiovascular
disease: beyond attenuation of traditional risk factors. Nature Reviews Cardiology.
2018;15(12):731-43.
Adamu B, Sani M, Abdu A. Physical exercise and health: a review. Nigerian Journal of
Medicine. 2006;15(3):190-6.
Fang J, Wylie-Rosett J, Cohen HW, Kaplan RC, Alderman MH. Exercise, body mass
index, caloric intake, and cardiovascular mortality. American journal of preventive
medicine. 2003;25(4):283-9.
Ryan AS. Exercise in aging: its important role in mortality, obesity and insulin resistance.
Aging health. 2010;6(5):551-63.
Rakowski W, Mor V. The association of physical activity with mortality among older
adults in the Longitudinal Study of Aging (1984–1988). Journal of Gerontology.
1992;47(4):M122-M9.
Imes CC, Lewis FM. Family history of cardiovascular disease (CVD), perceived CVD
risk, and health-related behavior: A review of the literature. The Journal of
cardiovascular nursing. 2014;29(2):108.
Chasandra M, Goudas M, Theodorakis Y. Exercise and smoking: a literature overview.
Health. 2015;7.

46

66.
67.

68.
69.
70.

71.
72.
73.
74.
75.

76.

77.

78.

79.
80.
81.

82.

83.

Monteiro D, Machado S, Moutão J et al. Physical exercise and sedentary lifestyle: health
consequences. Espiral. Cuadernos del Profesorado. 2019;12(25):75-88.
Tremblay MS, Colley RC, Saunders TJ, Healy GN, Owen N. Physiological and health
implications of a sedentary lifestyle. Applied physiology, nutrition, and metabolism.
2010;35(6):725-40.
Bouchard C, Depres JP, Tremblay A. Exercise and obesity. Obesity research.
1993;1(2):133-47.
Church T. Exercise in obesity, metabolic syndrome, and diabetes. Progress in
cardiovascular diseases. 2011;53(6):412-8.
Heffernan KS, Yoon ES, Sharman JE et al. Resistance exercise training reduces arterial
reservoir pressure in older adults with prehypertension and hypertension. Hypertens Res.
2013;36(5):422-7.
Banz WJ, Maher MA, Thompson WG et al. Effects of resistance versus aerobic training
on coronary artery disease risk factors. Exp Biol Med (Maywood). 2003;228(4):434-40.
Stewart KJ, Bacher AC, Turner KL et al. Effect of exercise on blood pressure in older
persons: a randomized controlled trial. Arch Intern Med. 2005;165(7):756-62.
Arroll B, Beaglehole R. Does physical activity lower blood pressure: A critical review of
the clinical trials. Journal of Clinical Epidemiology. 1992;45(5):439-47.
Vella CA, Kravitz L, Janot JM. A review of the impact of exercise on cholesterol levels.
IDEA Health & Fitness Source. 2001;19(10):48-54.
Boyden TW, Pamenter RW, Going SB et al. Resistance exercise training is associated
with decreases in serum low-density lipoprotein cholesterol levels in premenopausal
women. Arch Intern Med. 1993;153(1):97-100.
Hameed UA, Manzar D, Raza S, Shareef MY, Hussain ME. Resistance training leads to
clinically meaningful improvements in control of glycemia and muscular strength in
untrained middle-aged patients with type 2 diabetes mellitus. North American journal of
medical sciences. 2012;4(8):336.
Castaneda C, Layne JE, Munoz-Orians L et al. A randomized controlled trial of
resistance exercise training to improve glycemic control in older adults with type 2
diabetes. Diabetes Care. 2002;25(12):2335-41.
Couillard C, Després J-P, Lamarche B et al. Effects of endurance exercise training on
plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of
the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study.
Arteriosclerosis, thrombosis, and vascular biology. 2001;21(7):1226-32.
Evans WJ. Reversing sarcopenia: how weight training can build strength and vitality.
Geriatrics (Basel). 1996;51(5):46-7, 51-3; quiz 4.
Clark BC, Clark LA, Law TD. Resistance exercise to prevent and manage sarcopenia and
dynapenia. Annual Review of Gerontology and Geriatrics. 2016;36(1):205-28.
Schroeder EC, Franke WD, Sharp RL, Lee D-c. Comparative effectiveness of aerobic,
resistance, and combined training on cardiovascular disease risk factors: A randomized
controlled trial. PloS one. 2019;14(1):e0210292.
Fahlman MM, Boardley D, Lambert CP, Flynn MG. Effects of endurance training and
resistance training on plasma lipoprotein profiles in elderly women. J Gerontol A Biol Sci
Med Sci. 2002;57(2):B54-60.
Honkola A, Forsén T, Eriksson J. Resistance training improves the metabolic profile in
individuals with type 2 diabetes. Acta Diabetol. 1997;34(4):245-8.

47

84.

85.
86.
87.

88.

89.

90.
91.

92.

93.
94.

95.
96.

97.

98.
99.

100.

Durak EP, Jovanovic-Peterson L, Peterson CM. Randomized crossover study of effect of
resistance training on glycemic control, muscular strength, and cholesterol in type I
diabetic men. Diabetes care. 1990;13(10):1039-43.
Chernoff R. Nutrition and health promotion in older adults. The Journals of Gerontology
Series A: Biological Sciences and Medical Sciences. 2001;56(suppl_2):47-53.
Gaines JM, Talbot LA. Isokinetic Strength Testing in Research and Practice. Biological
Research For Nursing. 1999;1(1):57-64.
Sharp SA, Brouwer BJ. Isokinetic strength training of the hemiparetic knee: effects on
function and spasticity. Archives of physical medicine and rehabilitation.
1997;78(11):1231-6.
Timpka S, Petersson IF, Zhou C, Englund M. Muscle strength in adolescent men and risk
of cardiovascular disease events and mortality in middle age: a prospective cohort study.
BMC Medicine. 2014;12(1):62.
Magnussen CG, Schmidt MD, Dwyer T, Venn A. Muscular fitness and clustered
cardiovascular disease risk in Australian youth. European journal of applied physiology.
2012;112(8):3167-71.
Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality:
A narrative review. European journal of internal medicine. 2015;26(5):303-10.
Carbone S, Kirkman DL, Garten RS et al. Muscular strength and cardiovascular disease:
an updated state-of-the-art narrative review. Journal of Cardiopulmonary Rehabilitation
and Prevention. 2020;40(5):302-9.
Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult
population: results from the Third National Health and Nutrition Examination Survey,
1988-1991. Hypertension. 1995;25(3):305-13.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of
overweight and obesity in the United States, 1999-2004. Jama. 2006;295(13):1549-55.
Sempos CT, Cleeman JI, Carroll MD et al. Prevalence of high blood cholesterol among
US adults: an update based on guidelines from the second report of the National
Cholesterol Education Program Adult Treatment Panel. Jama. 1993;269(23):3009-14.
Artero EG, Lee D-c, Ruiz JR et al. A prospective study of muscular strength and allcause mortality in men with hypertension. J Am Coll Cardiol. 2011;57(18):1831-7.
Leblanc A, Taylor BA, Thompson PD et al. Relationships between physical activity and
muscular strength among healthy adults across the lifespan. Springerplus. 2015;4(1):110.
Nunes PRP, Barcelos LC, Oliveira AA et al. Effect of resistance training on muscular
strength and indicators of abdominal adiposity, metabolic risk, and inflammation in
postmenopausal women: controlled and randomized clinical trial of efficacy of training
volume. Age. 2016;38(2):40.
Clark BC, Manini TM. Sarcopenia ≠ Dynapenia. The Journals of Gerontology: Series A.
2008;63(8):829-34.
Fragala MS, Cadore EL, Dorgo S et al. Resistance training for older adults: position
statement from the national strength and conditioning association. The Journal of
Strength & Conditioning Research. 2019;33(8).
Carrasco-Rios M, Ortolá R, Rodríguez-Artalejo F, García-Esquinas E. Exposure to
secondhand tobacco smoke is associated with reduced muscle strength in US adults.
Aging (Albany NY). 2019;11(24):12674.

48

101.
102.
103.

104.

105.

106.

107.
108.

109.

110.
111.

112.
113.

114.

115.
116.

117.

Kok MO, Hoekstra T, Twisk JW. The longitudinal relation between smoking and muscle
strength in healthy adults. Eur Addict Res. 2012;18(2):70-5.
Abate M, Vanni D, Pantalone A, Salini V. Cigarette smoking and musculoskeletal
disorders. Muscles Ligaments Tendons J. 2013;3(2):63-9.
Rom O, Kaisari S, Aizenbud D, Reznick AZ. Identification of possible cigarette smoke
constituents responsible for muscle catabolism. J Muscle Res Cell Motil. 2012;33(34):199-208.
Petersen AM, Magkos F, Atherton P et al. Smoking impairs muscle protein synthesis and
increases the expression of myostatin and MAFbx in muscle. Am J Physiol Endocrinol
Metab. 2007;293(3):E843-8.
Darabseh MZ, Maden-Wilkinson TM, Welbourne G et al. Fourteen days of smoking
cessation improves muscle fatigue resistance and reverses markers of systemic
inflammation. Scientific reports. 2021;11(1):1-11.
Degens H, Gayan-Ramirez G, van Hees HW. Smoking-induced skeletal muscle
dysfunction. From evidence to mechanisms. American journal of respiratory and critical
care medicine. 2015;191(6):620-5.
Sesboüé B, Guincestre J-Y. Muscular fatigue. In: Proceedings of the Annales de
réadaptation et de médecine physique. 2006. p. 348-54.
Pasdar Y, Darbandi M, Mirtaher E, Rezaeian S, Najafi F, Hamzeh B. Associations
between muscle strength with different measures of obesity and lipid profiles in men and
women: results from RaNCD cohort study. Clinical nutrition research. 2019;8(2):148-58.
De Stefano F, Zambon S, Giacometti La et al. Obesity, muscular strength, muscle
composition and physical performance in an elderly population. The journal of nutrition,
health & aging. 2015;19(7):785-91.
Ruiz JR, Sui X, Lobelo F et al. Association between muscular strength and mortality in
men: prospective cohort study. BMJ. 2008;337:a439.
Tarp J, Støle AP, Blond K, Grøntved A. Cardiorespiratory fitness, muscular strength and
risk of type 2 diabetes: a systematic review and meta-analysis. Diabetologia.
2019;62(7):1129-42.
Wang Y, Lee D-c, Brellenthin AG et al. Association of muscular strength and incidence
of type 2 diabetes. In: Proceedings of the Mayo Clinic Proceedings. 2019. p. 643-51.
Häkkinen K, Pakarinen A. Muscle strength and serum testosterone, cortisol and SHBG
concentrations in middle‐aged and elderly men and women. Acta Physiologica
Scandinavica. 1993;148(2):199-207.
Karakas M, Schäfer S, Appelbaum S et al. Testosterone levels and type 2 diabetes—No
correlation with age, differential predictive value in men and women. Biomolecules.
2018;8(3):76.
Beatrice AM, Dutta D, Kumar M et al. Testosterone levels and type 2 diabetes in men:
current knowledge and clinical implications. Diabetes Metab Syndr Obes. 2014;7:481-6.
Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and
risk of type 2 diabetes: a systematic review and meta-analysis. Jama. 2006;295(11):128899.
Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent
Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes. The Journal of
Clinical Endocrinology & Metabolism. 2004;89(11):5462-8.

49

118.

119.

120.

121.
122.
123.

124.
125.

126.
127.

128.
129.

130.
131.
132.

Kapoor D, Goodwin E, Channer K, Jones T. Testosterone replacement therapy improves
insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in
hypogonadal men with type 2 diabetes. European Journal of Endocrinology.
2006;154(6):899-906.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2
diabetes, visceral obesity and partial androgen deficiency. The Aging Male. 2003;6(1):17.
Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective
role of estrogen and estrogen receptors in cardiovascular disease and the controversial use
of estrogen therapy. Biology of Sex Differences. 2017;8(1):33.
Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease.
Epidemiol Rev. 1985;7:89-104.
Baker L, Meldrum KK, Wang M et al. The role of estrogen in cardiovascular disease.
Journal of Surgical Research. 2003;115(2):325-44.
Wells CC, Riazi S, Mankhey RW, Bhatti F, Ecelbarger C, Maric C. Diabetic nephropathy
is associated with decreasedcirculating estradiol levels and imbalance in the expression of
renal estrogen receptors. Gender Medicine. 2005;2(4):227-37.
Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. Journal of
Laboratory and Clinical Medicine. 2001;137(4):231-43.
Brooks JM, Titus AJ, Bruce ML et al. Depression and Handgrip Strength Among U.S.
Adults Aged 60 Years and Older from NHANES 2011–2014. The journal of nutrition,
health & aging. 2018;22(8):938-43.
Roubenoff R, Hughes VA. Sarcopenia: current concepts. The Journals of Gerontology
Series A: Biological Sciences and Medical Sciences. 2000;55(12):M716-M24.
Mitchell WK, Atherton PJ, Williams J, Larvin M, Lund JN, Narici M. Sarcopenia,
dynapenia, and the impact of advancing age on human skeletal muscle size and strength;
a quantitative review. Frontiers in physiology. 2012;3:260.
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393(10191):2636-46.
Morley JE, Argiles JM, Evans WJ et al. Nutritional recommendations for the
management of sarcopenia. Journal of the american Medical Directors association.
2010;11(6):391-6.
Doherty TJ. Invited review: aging and sarcopenia. Journal of applied physiology. 2003.
Clark BC, Manini TM. Functional consequences of sarcopenia and dynapenia in the
elderly. Current opinion in clinical nutrition and metabolic care. 2010;13(3):271.
Manini TM, Clark BC. Dynapenia and aging: an update. Journals of Gerontology Series
A: Biomedical Sciences and Medical Sciences. 2012;67(1):28-40.

50

Appendices
Appendix A: NHANES Variable Names and Coding
MEASUREMENT

VARIABLE

DEFINITION

CODING COMMENTS

MUSCULAR
STRENGTH
AGE (AND DEMOS)

MSDPF

PF, Newtons

Continuous

RIAGENDR

Gender

0=male; 1=female

RIDAGEYR

Age

Continuous - report mean ± SD

RIDRETH1

Race

INDFMPIR

Family PIR

MCQ250F

Blood relatives
w/hypertension/stroke

1 = Mexican American
2 = Other Hispanic
3 = Non-Hispanic White
4 = Non-Hispanic Black
5 = Non-Hispanic Race/Multiracial
Low: 0 = else; 1 = less than 1.5
Mid: 0 = else; 1 = between 1.5 and 3.4
High: 0 = else; 1 = 3.5 and above
Turned into dichotomous variable:

MCQ250G

Blood relatives have
angina

0 = no family history of hypertension/stroke/angina;
1 = yes family history (either yes to MCQ250F or
MCQ250G)

SMOKING

LBXCOT

Serum cotinine
(ng/mL)

0 = Below 3.0 ng/mL;
1 = 3.0 ng/mL and above

SEDENTARY
LIFESTYLE

PAQ180

0 = A score of 2, 3, or 4 on the questionnaire
1 = A score of 1 on the questionnaire

OBESITY

BMXWAIST

Average level of
physical activity each
day, 1-4
Waist Circumference
(cm)

HYPERTENSION

BPQ040A

FAMILY HISTORY

BPXSAR

BPXDAR

DIABETES/BLOOD
GLUCOSE

DIQ010
LBXGLU

CHOLESTEROL/LOW
HDL

Prescribed
hypertension
medicine
Average systolic
blood pressure of 3-4
measures
Average diastolic
blood pressure of 3-4
measures
Doctor told you have
diabetes
Glucose, plasma
(mg/dL)

0 = Below 102 cm in males and 89 cm in females
1 = 102 cm and above in males and 89 cm and above in
females
0 = no medication
Turned into dichotomous
1= yes medication
variable:
0 = below 130 mmHg
1 =130 mmHg and above
0 = below 80 mmHg
1 = 80 mmHg and above
0 = no medication
1= yes medication
0 = below 100 mg/dL
1= 100 mg/dL and above

LBDLDL

LDL-cholesterol
(mg/dL)

0 = below 130 mg/dL
1= 130 mg/dL and above

LBDHDL

HDL-cholesterol
(mg/dL)

0 = 40 mg/dL and above
1 = below 40 mg/dL

BPQ100D

Taking Cholesterol
Medication

0 = no medication
1= yes medication

0 = no hypertension;
1 = yes hypertension (either
yes to BPQ040A or
BPXSAR or BPXDAR)

Turned into dichotomous
variable:
0 = no diabetes;
1 = yes diabetes (either yes
to DIQ010 or LBXGLU)
Turned into dichotomous
variable:
0 = no poor cholesterol;
1 = yes poor cholesterol
(either yes to LBDLDL or
LBDHDL or BPQ100D)
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ELEVATED HDL

LBDHDL

CARDIOVASCULAR
DISEASE

MCQ160B

MCQ160C

MCQ160E
MCQ160F

HDL-cholesterol
(mg/dL)
Ever told had
congestive heart
failure

0 = above 60 mg/dL
1 = 60 mg/dL and below
0 = no
1= yes

Ever told you had
coronary heart
disease
Ever told you had
heart attack
Ever told you had a
stroke

0 = no
1= yes
0 = no
1= yes
0 = no
1= yes

Turned into dichotomous
variable:
0 = no CVD history;
1 = yes CVD history
(either yes to MCQ160B or
MCQ160C or MCQ160E or
MCQ160F)
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